Celsus Therapeutics Plc Receives Approval from the Ministry of Health of Israel For Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients

NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis. Click here for the full press release

The release as fetched from its publisher. akaritx.com ↗